One approach that may overcome, in part, the problem of poor engraftment and augment the myocardial content of CPCs (thereby augmenting therapeutic efficacy) is to perform multiple CPC injections. Even if after subsequent injections the cells disappear at the same rate at which they disappear after the first, each injection should result in a transient spike in the number of CPCs in the tissue, such that the average density of these cells over time should be higher. Surprisingly, no previous study has been performed to 
A lthough administration of c-kit
POS cardiac progenitor cells (CPCs) has produced encouraging results in preclinical animal models of ischemic cardiomyopathy and in a phase I clinical trial, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] the effects of these cells have been regarded as modest or disappointing, and their therapeutic use (and that of adult cell therapy in general) questioned. [12] [13] [14] [15] [16] A major factor limiting the benefits of CPC therapy is the poor engraftment of transplanted cells. We have demonstrated that, after intracoronary or intramyocardial injection of syngeneic CPCs in mice, rats, and pigs, the number of cells remaining in the heart declines precipitously to very low values [4] [5] [6] [7] [17] [18] [19] [20] ; for example, <8% of the CPCs present immediately after transplantation remain in the mouse heart 1 week later, and after 35 days this number is <3%. 17, 18 Rapid disappearance of transplanted cells has also been observed with most other cells types, 1, 2, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] indicating that poor engraftment is a universal problem in cell therapy. Thus, strategies that increase the presence of CPCs in the heart may greatly enhance the therapeutic benefits of these cells and, conceivably, other cell types as well.
evaluate the effects of repeated CPC administrations. More generally, in the field of cell therapy at large, the overwhelming majority of the studies performed heretofore have evaluated efficacy on the basis of a single treatment; very few studies [32] [33] [34] [35] [36] have used repeated doses. The problem with using a single dose is that, as the myocardial content of progenitor cells declines rapidly after transplantation, irrespective of which cell type is used, 1,2,4-7,17-31 injecting a cell product only once may not be an adequate test of the efficacy of that product; for the therapeutic effects to become apparent, repeated doses may be necessary to replace the cells that die after transplantation. Just as most pharmacological agents are ineffective when given once but can be highly effective when given repeatedly, so a cell product that seems to be ineffective or modestly effective when given as a single treatment may, in fact, turn out to be efficacious if given repeatedly. If this concept is correct, the current paradigm of cell therapy would change dramatically.
The goal of the present investigation was to test this hypothesis. Specifically, we sought to determine whether 3 administrations of CPCs, performed 35 days apart, result in greater improvement in left ventricular (LV) structure and function compared with a single CPC administration. Because ischemic heart failure seems to be the clinical setting in which cell therapy offers the greatest promise, 1, 2 we used a rat model of ischemic cardiomyopathy caused by an old myocardial infarction (MI), in which CPC administration has previously been found to be beneficial. 6 Our finding that 3 doses of CPCs are markedly more effective than a single dose has potentially far-reaching implications for cell therapy.
Methods
A detailed Methods section is included in the Online Data Supplement.
Isolation, Culture, and Transfection of c-kit

POS
CPCs
CPCs were isolated from the entire heart (atria and ventricles) of adult male Fischer 344 rats as described 4 and phenotyped by fluoresence-activated cell sorting (FACS) analysis of fixed cells. The cells were injected into rat hearts at passages 6 to 8. The rationale for using male donor CPCs was that the fate of transplanted CPCs can be tracked by detecting Y-chromosome pos cells, although previous studies have suggested that bone marrow-derived mesenchymal stromal cells differ significantly between male and female sources, with female cells usually performing more robustly. 37 
Surgical Procedures, Treatment Protocol, and Preliminary Studies
The rat model of old MI has been described previously. 6 Adult female Fischer 344 rats (age, 4 months; weight 175±2 g) underwent a 2-hour occlusion of the left anterior descending coronary artery followed by reperfusion. Thirty days after surgery, the animals were randomly allocated to 3 treatment groups: vehicle (control), single dose, or multiple doses (Figure 1 ). Randomization was performed using the MS Excel random group generator.
All rats received an echo-guided intraventricular injection, which was performed using the Vevo 2100 Imaging System (VisualSonics) equipped with a 20-MHz transducer, a Vevo Image Station with Injection Mount and micromanipulation controls, and a Chemyx NanoJet Stereotaxic syringe pump (Chemyx Inc, TX). Before the procedure, rats were anesthetized with 3% isoflurane. The anterior chest was shaved, and the animals were placed on the imaging table in the right lateral decubitus position with the left lateral side facing the injection mount. Light anesthesia was maintained with 1% isoflurane. With the imaging transducer aligned perpendicularly to the injection mount, the left ventricle was initially imaged in the parasternal plane, and a good 2-dimensional (2D) long-axis view was procured by adjusting the angle and position of the imaging table. The transducer was then turned 90° clockwise, and the left ventricle was scanned in the 2D short-axis and color Doppler views from apex to base to determine the optimal site for needle insertion, a site that did not include the infarct scar or a coronary artery. Under the guidance of a real-time B-mode view, a 30 G injection needle (1″ length) was then carefully inserted from the left lateral side using the micromanipulation controls and advanced into the center of the LV cavity.
Rats received an infusion of CPCs (12×10 6 cells in 5 mL of DPBS (Dulbecco phosphate-buffered saline, Gibco) or vehicle (5 mL of DPBS) into the LV cavity with the injection pump at a rate of 1.25 mL/min for 4 minutes. The single-and multiple-dose groups received CPCs, whereas the vehicle group received DPBS. Thirty-five days later, this procedure was repeated; rats received a second infusion of CPCs (multiple-dose group) or an infusion of DPBS (single-dose and vehicle groups). Thirty-five days later, rats received a third infusion of CPCs (multiple-dose group) or another infusion of DPBS (single-dose and vehicle groups). mCherry-labeled CPCs were used for the first treatment, nonlabeled CPCs for the second treatment, and green fluorescent protein (GFP)-labeled CPCs for the third treatment. To monitor the formation of new cells, in all groups, 5-bromo-2′-deoxyuridine (BrdU, Sigma) was given for 35 days after the first treatment and 5-iodo-2′-deoxyuridine (IdU, Sigma) for 35 days after the third treatment (both were given in the drinking water at a final concentration of 0.1%). At 35 days after the third treatment, rats were subjected to hemodynamic studies and euthanized for histological studies or polymerase chain reaction (PCR) analysis ( Figure 1) .
Before initiating the protocol, pilot studies were conducted to identify a dose of CPCs that would result in LV myocardial retention similar to that observed after intracoronary infusion of 1 million CPCs, the dose used in our previous studies in rats. 3, 4, 6 Rats underwent a 90-minute coronary occlusion and reperfusion. Four hours after reperfusion, they received 1.0×10 6 CPCs (in 1 mL of DPBS) via intracoronary infusion as in our previous studies, [3] [4] [5] [6] 3.0, 9.0, or 12.010 6 CPCs (in 5 mL of DPBS over 4 minutes) using echo-guided injection into the LV cavity, or 3.0×10 6 CPCs intravenously. Rats were euthanized 24 hours after CPC delivery, and the heart was harvested to measure the number of CPCs in the tissue by real-time PCR.
Echocardiographic Studies
All echocardiographic analyses were performed by investigators who were blinded to treatment allocation. Serial echocardiograms were obtained at 5 time points: baseline (3 days before coronary artery occlusion), 30 days after MI (before the first treatment), 35 days after the first treatment (before the second treatment), 35 days after the second treatment (before the third treatment), and 35 days after the third treatment (before euthanasia; Figure 1 ). The echocardiographic studies were performed as described [3] [4] [5] [6] using a Vevo 2100 Imaging System equipped with a 20-MHz transducer.
Hemodynamic Studies
All hemodynamic analyses were performed by investigators who were blinded to treatment allocation. The hemodynamic studies were conducted 35 days after the third treatment, just before euthanasia (Figure 1) . The protocol has been described. 
Histological Studies
The protocol for histological analyses has been described. [4] [5] [6] [7] 38 Immunohistochemistry was performed in formalin-fixed, paraffinembedded, 4-µm thick heart sections. To assess the fate of the transplanted male CPCs, single-labeled Y-chromosome was detected by fluorescence in situ hybridization according to the modified manufacturer's protocol (ID Laboratories, London, ON).
4,39
Measurement of Transplanted Cells by Real-Time PCR
To determine the absolute number of transplanted CPCs, a quantitative real-time PCR-based method was used as previously described 17, 18 in a subset of hearts from the single-dose group (n=8) and the multipledose group (n=11), which were frozen just after excision.
Statistical Analysis
All data are expressed as means±SEM. Echocardiographic data were analyzed with 2-way repeated-measures ANOVA followed by the Student t tests with Bonferroni correction for intra-and intergroup comparisons, as appropriate. All parametric data including morphometric, histological, immunohistochemical, and hemodynamic data were analyzed by 1-way ANOVA followed by the Student t tests with Bonferroni correction for intergroup comparisons. [40] [41] [42] Mortality was analyzed by the χ 2 test. All analyses were conducted with SigmaStat 3.5. P values of <0.05 were considered significant.
Results
A total of 104 rats were included in this study: 19 for the preliminary dosing studies and 85 for the final protocol.
Characterization of CPCs
Online Figure IIA and IIB are representative confocal images of mCherry-and GFP-labeled c-kit POS CPCs. Similar to our previous studies, 4, 5 FACS analysis showed that 82.9±2.2% (n=7) of the cells were c-kit positive at the passage when they were injected (passages 6-8); in addition, 80.8±5.4% (n=5) were mCherry positive and 97.6±0.4% (n=2) GFP positive (Online Figure IIC and IID). CPCs were negative for CD45 (0.5±0.1%, n=5) and CD31 (0.4±0.0%, n=5), and expressed mesenchymal markers (CD 90, 19.7±9.8%, n=5; CD105, 68.1±6.5%, n=5; CD73, 92.2±4.6%, n=5; and CD29, 99.5±0.1%, n=5; Online Figure IID) . The mean population doubling time was 28.9±2.8 hours (n=5).
Preliminary Studies
We have previously found that 1×10 6 CPCs, delivered intracoronarily, produce an improvement in LV function in this rat model. 6 Preliminary studies were conducted in 19 rats to select a dose of CPCs that would result in a comparable degree of myocardial retention when delivered into the LV cavity. As shown in Table 1, intraventricular infusion of 3×10   6   , 9×10   6   ,  and 12×10 6 CPCs resulted, 24 hours later, in a dose-dependent retention of cells. Because the number of CPCs retained 24 hours after the 12×10 6 dose (112 983±56 300 cells/heart, n=6) was similar to that retained 24 hours after intracoronary infusion of 1×10 6 CPCs (118 924±24 458, n=3), and because, as mentioned above, the latter treatment is effective in enhancing LV function in this rat model, 6 we selected 12×10 6 CPCs as the dose to be used in this study. The equivalency of the intraventricular CPC dose used herein and the intracoronary CPC dose used previously is further supported by the fact that the benefits of 12×10 6 CPCs in the single-dose group (vide infra) were comparable to those observed previously in this same model after intracoronary infusion of 1×10 6 CPCs. 6 In contrast to the intraventricular infusion, no CPCs could be found in the heart after intravenous infusion of 3×10 6 CPCs (Table 1 ).
Exclusions and Gross Measurements
As shown in Online Table I , of the 85 rats that were subjected to coronary artery occlusion/reperfusion, 13 died within 7 days after MI. At 30 days after MI, the remaining 72 rats were assigned to 1 of the 3 treatment groups (vehicle, single dose, or multiple doses); 9 of these animals died after CPC infusion because of intrathoracic bleeding from the LV injection site. Thus, a total of 63 rats completed the protocol; of these, 2 were excluded because of prespecified criteria (1 because LV EF decreased to <15 U after MI and before treatment, as shown by echocardiography (Online Figure IA ) and 1 because of small scar size (<10% of risk region), as shown by trichrome stain (Online Figure IB) . Therefore, a total of 61 rats (16 in the vehicle group, 20 in the single-dose group, and 25 in the multiple-dose group) were included in the final analysis. Of these, 50 rats (16 in the vehicle group, 16 in the singledose group, and 18 in the multiple-dose group) underwent echocardiographic and hemodynamic studies, 42 (16, 12 , and 14, respectively) were used for pathological and immunohistochemical analyses, and 8 (4 in the single-dose group and 4 in the multiple-dose group) were used for quantitative PCR analysis of CPC retention. An additional 11 rats (4 in the single-dose group and 7 in the multiple-dose group) were used for quantitative PCR analysis without echocardiographic or hemodynamic analyses; 2 of these rats (in the multiple-dose group) were excluded because the CPC counts were >2 SD above the average, likely as a result of accidental injection of cells into the LV wall. Therefore, data from 17 rats (8 in the single-and 9 in the multiple-dose groups) were used for the quantitative PCR analysis of CPC retention (Online Table I ). There were no significant differences in body weight among the 3 groups throughout the experimental protocol (Online Table II ). Similarly, there were no significant differences among the groups with respect to LV weight or LV volume measured at postmortem examination (Online Table II ).
Echocardiographic Measurements
Echocardiographic measurements are summarized in Online Table III ; representative echocardiographic recordings are illustrated in Online Figure III . Before the first treatment (30 days after MI), LV end-diastolic volume and LV end-systolic volume (LVESV) were markedly increased from baseline ( Figure 2A ), whereas diastolic thickness and systolic thickening fraction (ThF) in the infarcted wall ( Figure 3A ) and LV EF ( Figure 4A and 4B) were markedly decreased. There were no significant differences among the vehicle, single-dose, and multiple-dose groups in any of these variables, indicating that before the first treatment, the severity of post-MI LV remodeling and dysfunction was comparable in all groups.
After the first treatment, however, the 3 groups exhibited a different course. As expected, the vehicle-treated (control) group continued to show progressive deterioration of both regional and global LV function (Figures 2-4 ; Online Figure  III) . Thus, in the 105-day interval between the first treatment and euthanasia, LVESV increased progressively compared with pretreatment values (at 30 days after MI; Figure 2B ), whereas diastolic thickness of the infarcted wall ( Figure 3B ), systolic ThF in the infarcted wall ( Figure 3B ), and LV EF ( Figure 4D ) all decreased progressively.
The single-dose group exhibited a significant improvement in indices of regional and global LV function after the first infusion (which consisted of CPCs); however, no further significant improvement was observed after the second and third infusions (which consisted of vehicle; Figures 2 through 4) . For example, compared with the vehicle group, administration of CPCs in the single-dose group resulted, 35 days later, in a decrease in LVESV (Figure 2A and 2B ) and in the percentage of the LV circumference that was akinetic (akinetic length; Figure 3C and 3D) and in an increase in the diastolic thickness in the infarcted wall ( Figure 3A and 3B) , in the ThF in the infarcted LV wall ( Figure 3A and 3B), as well as in LV EF ( Figure 4) ; after the second and third infusions (vehicle), none of these variables changed significantly (Figures 2 through 4) .
In contrast, the multiple-dose group exhibited a progressive improvement in regional and global LV function after each CPC infusion (Figures 2 through 4) . Each additional treatment produced additional benefit, and the magnitude of the improvement observed after the second and third infusions was roughly comparable to that observed after the first infusion (Figures 2  through 4) . Thus, compared with pretreatment values (at 30 days after MI), the diastolic thickness of the infarcted wall increased by 0.10±0.02 mm, 0.20±0.02 mm, and 0.32±0.03 mm after the first, second, and third infusions of CPCs, respectively (P<0.01 for second versus first and third versus 2 nd ; Figure 3B ); systolic ThF in the infarcted wall increased by 8.5±2.4%, 16.5±2.8%, and 22.3±3.9% (P<0.05 for second versus first and third versus second; Figure 3B ); LVESV decreased by 10.2±4.0 µL, 18.2±3.5 µL, and 24.2±5.5 µL (P<0.05 for second versus first; Figure 2B ); LV EF increased by 3.4±0.5%, 7.4±0.9%, and 13.0±0.8% (P<0.01 for second versus first and third versus second; Figure 4D ); and the percentage of the LV circumference that was akinetic (akinetic length) decreased by 5.6±2.6%, 10.5±2.4%, and 13.6±2.0% ( Figure 3D ).
As a result of this stepwise improvement, the cumulative beneficial effects of cell therapy after 3 CPC infusions were much greater than the effects seen after 1 CPC infusion. For example, the total (cumulative) increase in LV EF between pretreatment and end of the study in the multiple-dose group (13.0±0.8%) was approximately triple that in the single-dose group (4.7±0.8%; P<0.01; Figure 4D ). The total (cumulative) increase in infarcted wall ThF was ≈2.5 greater in the former (22%) than in the latter (9%; P<0.05; Figure 3B ). Similarly, the total (cumulative) decrease in akinetic length was ≈2.5× greater in the multiple-dose group than in the single-dose group (−13.6% versus −5.6%, P<0.05; Figure 3D ). The greater therapeutic efficacy of multiple CPC infusions is further demonstrated by the fact that, at the end of the protocol, there were statistically significant differences in infarcted wall thickness, infarcted wall ThF, LV EF, LVESV, and akinetic length not only between the multiple-dose group and the vehicle group but also between the multiple-dose group and the single-dose group (P<0.01 for all comparisons; Figures 2 through 4 ). An additional difference is that in the multiple-dose group, the systolic ThF in the posterior (noninfarcted) LV wall was significantly greater than in the vehicle group after the second and third treatments (P<0.01); in contrast, in the single-dose group, systolic ThF in the posterior wall was significantly (P<0.01) greater than in the vehicle group only after the third treatment ( Figure 3A) .
For LV EF, repeated-measures 2-way ANOVA demonstrated a significant interaction between time and group (F=35.57, P<0.001), indicating that the relationship between LV function and time depended on the treatment group. Similar conclusions were achieved for LVESV, LV stroke volume, diastolic thickness of the infarcted wall, systolic ThF in the infarcted wall, and akinetic length (Figures 2 and 3 ). Trend analysis indicated that (1) in the vehicle group, LV EF declined significantly over time (P<0.001); (2) in the single-dose group, a single linear trend could not capture the EF profile over time because EF increased after the first treatment (P<0.001) but plateaued after the second and third treatments; and (3) in the multiple-dose group, LV EF increased significantly over time (P<0.001) and the LV EF profile could be captured by a linear trend. Similar conclusions were achieved when trend analysis was used for the other variables illustrated in Figures 2 and 3 . In summary, the patterns observed in the 3 treatment groups were different: indices of regional and global LV function improved after each treatment (by a similar amount) in the multiple-dose group, improved only after the first treatment in the single-dose group, and either worsened or were unchanged after each treatment in the vehicle group.
Echocardiography did not demonstrate any significant effect of CPCs on LV dilatation. As shown in Figure 2A , LV end-diastolic volume remained relatively stable in vehicle-treated rats during the 3 treatments and was not affected by either single or multiple administrations of CPCs ( Figure 2A ). The observation that CPCs did not reverse LV dilatation is consistent with our previous studies in this rat model of old MI. 6 
Hemodynamic Measurements
The hemodynamic studies, which were performed just before euthanasia, also demonstrated superior LV function in the multiple-dose group compared with the single-dose group (Figure 5A and 5B; Online Table IV) . Both of these groups exhibited a significant improvement in most hemodynamic parameters compared with the vehicle group; however, the efficacy of multiple treatments was superior to that of a single treatment, as demonstrated by the fact that LV EF (a load-dependent index of LV systolic function) and preload recruitable stroke work and end-systolic elastance (two load-independent indices) were significantly greater in the multiple-dose group versus the single-dose group, whereas ESV was significantly smaller ( Figure 5B ). Thus, 2 independent methods of functional assessment (echocardiography and hemodynamic studies with a conductance catheter) consistently demonstrated that multiple administrations of CPCs produced a greater improvement in regional and global LV function compared with a single administration.
Morphometric and Histological Analysis
As illustrated in Figure 6A , the vehicle group exhibited LV dilatation and an extremely thin infarcted wall with a confluent scar. In the single-and multiple-dose groups, the infarcted wall was thicker, and the amount of viable tissue within the risk region was greater compared with the vehicle group ( Figure 6A ). In each heart, a detailed quantitative analysis was performed on 2 sections (1 from each of 2 midventricular slices); the results are summarized in Figure 6B and Online Table V . Although the size of the risk region was similar among the 3 groups, both the single-and the multiple-dose groups exhibited a greater amount of viable myocardium within the risk region (60.6±2.2% and 67.7±2.9% of the risk region, respectively) than the vehicle group (51.4±2.3%, P<0.05 versus the single-dose group and P<0.01 versus the multiple-dose group). Unlike the single-dose group, however, the multipledose group also exhibited a significant increase in the thickness of the infarcted wall and in the percentage of LV weight that was accounted for by viable tissue (P<0.05 and P<0.01, respectively, versus the vehicle group; Figure 6B ). There was a trend for the percentage of scarred tissue to be smaller and the infarcted wall thickness and percentage of viable myocardium to be greater in the multiple-dose group compared with the single-dose group, but the differences were not statistically significant ( Figure 6B ). Taken together, the morphometric data confirm the echocardiographic finding of greater infarcted wall thickness in the multiple-dose group than in the singledose group ( Figure 3A ) and reveal a difference between single and multiple treatments with respect to the amount of viable myocardium: both treatments increased viable tissue and decreased scar within the risk region, but when these variables were expressed as percentages of the entire left ventricle, only multiple treatments were associated with an increase in the total amount of viable tissue and a decrease in the total scar burden.
Myocardial fibrosis plays a key role in the pathology of LV remodeling after MI. 43 In the noninfarcted region, collagen content was significantly less in the multiple-dose group compared with the single-dose group (P<0.05; Figure 6C and 6D). This reduced collagen deposition in the myocardium may have contributed, at least in part, to the functional benefits of CPC therapy.
Myocyte Cross-Sectional Area and Myocyte and Vessel Density
Myocyte cross-sectional area and myocyte density were assessed by staining myocytes with an anti-α-sarcomeric actin antibody and myocyte membranes with FITC-conjugated wheat germ agglutinin (WGA) to facilitate counting individual myocytes ( Figure 7 and Online Figure IV ). In the noninfarcted region, there were no significant differences among groups ( Figure 8B and 8C). However, in the risk region, myocyte cross-sectional area was significantly smaller and myocyte density was significantly greater in the 2 treated groups compared with the vehicle group ( Figure 7B and 7C); in the multiple-dose group, these changes were more pronounced, such that both myocyte cross-sectional area and density were significantly different from the single-dose group (P<0.05; Figure 7B and 7C). Consistent with these data, analysis of the 
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distribution of cardiomyocyte cross-sectional area demonstrated no difference in the noninfarcted region but a shift to the left in the risk region in the single-dose group and, even more so, in the multiple-dose group (Online Figure IV) . Although other explanations are possible, increased myocyte density is consistent with increased formation of new myocytes. Vascular density was assessed by staining tissue sections with FITC-conjugated isolectin B4 (Online Figure V) . In all the groups, vascular density was significantly less in the risk region than in the noninfarcted region, but no differences were noted among the 3 groups.
Survival of Transplanted CPCs
Survival of transplanted CPCs was assessed by 2 independent methods. The CPCs administered during the first infusion were labeled with mCherry and those infused during the third infusion with GFP ( Figure 1 ). As shown in Table 2 , at the end of the study (35 days after the third CPC infusion and 105 days after the first infusion), very few GFP POS cells and even fewer mCherry POS cells were found in the left ventricle using immunohistochemistry (n=14). In addition, the number of CPCs remaining in the heart at the end of the protocol was measured using quantitative real-time PCR in 2 subsets of rats (Online Table VI ). Transplanted CPCs were detected only in 5 of the 8 rats analyzed in the single-dose group and in 9 of the 11 rats analyzed in the multiple-dose group. In the hearts with detectable CPCs, the number of these cells was extremely low: 3330±1451 in the entire heart in the single-dose group (n=5) and 5078±1409 in the multiple-dose group (n=7; P=NS). Assuming that no cells were present in hearts with no detectable CPCs, the total content of CPCs averaged 2081±1060 cells in the single-dose group (n=8) and 3950±1310 in the multiple-dose group (n=9; P=NS). Thus, the number of transplanted cells that was engrafted in the heart was very low; it tended to increase after 3 CPC infusions versus a single infusion, but the difference was not statistically significant, possibly because of the large variability.
Analysis of Cell Proliferation
In previous studies, we have observed a pronounced and prolonged proliferative response to a single CPC administration. 4, 6 To determine the effect of multiple CPC doses on cell proliferation, rats were given BrdU for 35 days after the first treatment (days 1-35 after start of therapy) and IdU for 35 days after the third treatment (days 71-105 after start of therapy; Figure 1 ). In all the 3 groups, the number of BrdU POS and IdU POS cells was significantly greater in the risk region than in the noninfarcted region ( Figure 8C through 8F ), indicating greater cell proliferation and/or greater infiltration of proliferating cells in the former, a finding consistent with our previous observations. 4, 6 In the noninfarcted region, there were no significant differences among the 3 treatment groups with respect to either BrdU POS or IdU POS cells ( Figure 8C through 8F) . In contrast, http://circres.ahajournals.org/ Downloaded from significant differences were noted in the risk region. In vehicle-treated hearts, 13.8±1.0% of nuclei in the risk region were BrdU POS ( Figure 8C ) and 22.2±1.9% IdU POS ( Figure 8D ) at the end of the study, indicating that a substantial number of new cells were formed between days 1 and 105 (BrdU POS cells) and between days 71 and 105 after the beginning of treatment (IdU POS cells). These values are consistent with our previous results. 4, 6 A single dose of CPCs did not result in a significant increase in BrdU POS cells ( Figure 8C) ; this, however, does not rule out a proliferative response to CPCs because BrdU was given only for the first 35 days after CPC infusion and cells may have proliferated early after CPC infusion and then died by the time rats were euthanized 105 days later. A single dose of CPCs did produce a significant increase in the number of IdU POS cells ( Figure 8D ), indicating that at 71 to 105 days after the administration of CPCs, there was increased cell proliferation. The ability of a single CPC infusion to promote cell proliferation several months later is consistent with our previous findings in this rat model. 4, 6 The number of BrdU POS / IdU POS (double positive) cells was not significantly increased 105 days after a single CPC administration ( Figure 8E ), but again, an early proliferative response may have been missed if significant numbers of BrdU POS cells died before euthanasia. This possibility is supported by the fact that, in the vehicletreated group, the number of IdU POS cells (22.2±1.9% in risk region and 14.6±0.8% in noninfarcted region) was greater than the number of BrdU POS cells (13.8±1.0% in risk region and 10.8±1.0% in noninfarcted region; Figure 8C and 8D).
In rats that received multiple doses of CPCs, the number of BrdU POS cells was markedly increased versus both the single-dose group and the vehicle group ( Figure 8C ), suggesting that the second and third infusions of CPCs induced a robust proliferative response (on days 36-105 after the beginning of CPC treatment). The number of IdU POS cells was significantly increased versus the vehicle group but not versus the single-dose group (Figure 8D ), suggesting that although 3 CPC doses produced a robust proliferation on days 71 to 105 after the beginning of treatment, this proliferation was not greater than that induced by a single treatment given earlier.
Unlike the single-dose group, the multiple-dose group exhibited a significant increase in the number of BrdU ) cells were combined, their number was significantly increased after both a single and multiple CPC infusions ( Figure 8F) ; the increase tended to be greater after multiple CPC infusions, but the difference versus the single-dose group was not significant.
Taken together, these data indicate that a single CPC infusion promoted a sustained proliferative response in the risk region (or a greater infiltration of inflammatory cells in the risk region) that was still evident 2 to 3 months (71-105 days) later, and that multiple CPC infusions tended to further augment this response.
Analysis of New Myocyte Formation.
Formation of new mature myocytes was assessed by measuring the number of BrdU POS or IdU POS cells that expressed cTnI and exhibited a morphology typical of adult myocytes ( Figure 8 ). (Thus, the small cells that express α-sarcomeric actin but lack the morphology of mature cardiomyocytes [cells that we observed after CPC transplantation in our previous studies 4, 6 ] were not included in this analysis.) In Figure 8 , the number of new mature myocytes (BrdU POS /cTnI POS or IdU POS /cTnI POS cells) is expressed both as a percent of total nuclei ( Figure 8G through 8J) and as a percent of total myocytes ( Figure 8K through 8N) . In all groups, these cells tended to be more abundant in the noninfarcted than in the risk region but, in absolute terms, they were rare. For example, in the vehicle-treated group, the number of BrdU POS or IdU POS mature myocytes was <0.5% of the nuclei and <0.5% of myocytes both in the risk region and in the noninfarcted region ( Figure 8G through 8N) . The density of these cells was not significantly increased by a single CPC infusion ( Figure 8G through 8N) . Three CPC infusions were associated with a significant increase Figure 7 . Analysis of myocyte cross-sectional area and myocyte density. Myocyte cross-sectional area and myocyte density were determined in rat hearts stained with wheat germ agglutinin (WGA; green) and anti-α-sarcomeric actin (α-SA; red). A, Representative epifluorescent microscopic image, sequentially acquired from 18 fields of the infarcted region of a vehicle-treated rat at a magnification of ×300. Myocytes with round nuclei and clearly defined sarcolemmal borders were selected for analysis of cross-sectional area. Quantitative analyses of myocyte cross-sectional area (B) and myocyte density (C) per mm 2 . WGA binds to the myocyte membrane, thereby facilitating the evaluation of myocyte cross-sectional area and density. The risk region comprises both the border zones and the infarcted region. Data are means±SEM. Bar is 100 µm. in BrdU POS and IdU POS mature myocytes in the risk region (P<0.05 versus vehicle-treated rats; Figure 8G through  8N ), but even in this group, the percentage of these cells was very low (<0.5% of nuclei and <2% of myocytes in the risk region and <1% of nuclei and <1% of myocytes in the noninfarcted region).
Taken together, these data indicate that the number of newly formed mature myocytes was very small in the absence of CPC infusion and did not change after a single infusion; although this number increased significantly after 3 CPC infusions, it was still extremely low in absolute terms, and, thus, not sufficient to account for the improvement in function.
Analysis of Y-Chromosome pos Cells
To assess the fate of transplanted male CPCs, the number of Y-chromosome pos cells was measured by fluorescence in situ hybridization. The advantage of using the Y-chromosome to track transplanted cells in long-term studies is that, unlike GFP or β-galactosidase, its presence is not affected by the changes in gene expression.
44-46 Y-chromosome pos cells were detected both in the single-dose group and in the multiple-dose group, but they were significantly more abundant in the multipledose group, both in the risk and in the noninfarcted region ( Figure 9C and 78.4±6.0% were nonmyocytes. Consequently, the number of Y-chromosome pos myocytes was minuscule both in the single-dose group and in the multiple-dose groups: 0.25±0.05% and 0.37±0.07% of total nuclei, respectively, in the risk region, and 0.25±0.11% and 0.54±0.17%, respectively, in the noninfarcted region ( Figure 9D ). Similar values were obtained when Y-chromosome pos myocytes were expressed as a percentage of total myocytes: they accounted for <1% of myocytes in the risk region and <0.5% in the noninfarcted region ( Figure 9E ).
Taken together, these data indicate that, regardless of the number of CPC infusions, very few transplanted cells (or their progeny) engraft in the heart and, of these, only a small fraction differentiate into mature cardiomyocytes. Multiple CPC infusions produce an increase in CPC engraftment that is statistically significant but, in absolute terms, is quite small. Figure 9H ). This finding suggests that not all CPCs underwent cell cycling before differentiating into mature myocytes.
Discussion
The safety and efficacy of repeated CPC administrations are unknown because all previous studies have delivered these cells only once. The salient findings of the present investigation can be summarized as follows: (1) in a rat model of chronic ischemic cardiomyopathy, 3 CPC infusions performed 35 days apart produced a markedly greater improvement in both regional and global parameters of LV function compared with a single infusion; the superiority of multiple treatments was consistently observed with 2 independent techniques (echocardiography and hemodynamic studies); (2) both echocardiography and morphometry showed that the infarcted LV wall was significantly thicker in the multiple-dose group than in the vehicle group; (3) unlike 1 CPC infusion, 3 CPC infusions resulted in a significant decrease in the total LV scar burden, a significant increase in total LV viable tissue, and a significant decrease in collagen content in the noninfarcted region; (4) both a single and multiple CPC treatments promoted sustained cellular proliferation (or infiltration of inflammatory cells) in the risk region, but this effect tended to be more pronounced in the latter group; (5) despite the remarkable functional benefits conferred by CPC infusion, the number of transplanted cells remaining in the heart at the end of the study was minuscule (≈2000 cells/heart in the single-dose group and ≈4000 cells/heart in the multiple-dose group); (6) regardless of the number of CPC infusions, few (<10%) of the transplanted cells that remained in the heart at the end of the study differentiated into mature cardiomyocytes, and <1% of all myocytes were derived from transplanted cells; (7) both a single and multiple CPC infusions resulted in a decrease in myocyte cross-sectional area and an increase in myocyte density in the risk region, but these changes were significantly greater in the multiple-dose group; (8) unlike a single CPC infusion, multiple CPC infusions were associated with a significant increase in new (BrdU POS or IdU POS ) mature myocytes in the risk region versus vehicletreated rats; however, even after multiple CPC infusions, the absolute number of newly formed (BrdU POS or IdU POS ) myocytes was very small (<1% of total nuclei and <2% of total myocytes).
Taken together, these results demonstrate that 3 repeated doses of CPCs are safe and considerably more effective in improving LV performance and structure than a single CPC dose, and that these effects cannot be ascribed to differentiation of transplanted cells into myocytes. Many previous investigations have examined the effects of various cells types in models of ischemic cardiomyopathy. 2 However, to our knowledge, this is the first study to examine the effects of repeated administrations of CPCs or any cardiac-derived cell type. One of the most important findings of this study is that each CPC infusion was associated with a similar degree of improvement in regional and global LV function. For example, systolic ThF in the infarcted region (an index of regional function in this region) increased by 9 ThF units after the first CPC infusion, 8 ThF units after the second, and 5 ThF units after the third ( Figure 3B ). LVEF increased by 3.4 U after the first CPC infusion, 4.0 U after the second, and 5.5 U after the third ( Figure 4C ). These results suggest that each dose of CPCs produces a comparable improvement in LV function, at least within the first 3 treatments. Whether additional (>3) doses also produce similar effects remain to be determined. Nevertheless, the fact that the magnitude of benefit is relatively constant after each of the first 3 treatments implies that the potential benefits of cell therapy may be underestimated or even overlooked if they are measured after a single administration of cells, and that repeated administrations are necessary to properly evaluate the effectiveness of a cell product. For example, in this study the first CPC administration produced a modest (3.4%) increase in LVEF ( Figure 4C ). Depending on the experimental model and the power of the study, such a small increase may not always be detected, and so if one is using only one dose, it may be erroneously concluded that CPCs are ineffective; however, such an error would be unlikely after 3 doses because the 13% increase in LVEF observed in the multiple-dose group ( Figure 4D ) would be difficult to miss.
This study was designed to provide robust results. Large numbers of rats (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) were included in each group. LV function and structure were assessed by a painstaking echocardiographic analysis and by another, independent method (hemodynamic studies), and both sets of measurements were conducted blindly. A thorough pathological analysis was performed, and survival of transplanted cells was assessed by 3 independent methods (PCR-based assays, Y-chromosome analyses, and mCherry/GFP immunohistochemistry).
As mentioned above, no previous investigation has used multiple doses of CPCs. The few studies that have compared multiple and single cell doses have used skeletal myoblasts 34, 35 and unfractionated bone marrow cells 32, 33, 36 and have yielded discrepant results (one of these studies examined only 2 treatments 32 ). Yao et al 32 found that 2 intracoronary infusions of autologous bone marrow mononuclear cells, 3 months apart, in patients with large MI resulted in further improvement of LVEF and decrease in scar size compared with 1 infusion. Premaratne et al 35 reported that 3 repeated intramyocardial injections of skeletal myoblasts in rats starting 4 weeks after LAD ligation improved LV fractional area change (EF was not reported) and resulted in increased cell engraftment and LV elastance compared with a single injection. In contrast, Zhang et al 33 reported no additive effects, and actually a trend toward worsening LV function, in mice receiving 1, 2, or 3 intramyocardial injections of bone marrow cells after coronary ligation. Our current findings that multiple doses have an additive effect on LV function are consistent with the observations of Gavira et al. 34 These investigators injected 1, 2, or 3 doses of skeletal myoblasts transendocardially in pigs at 8, 14, and 20 weeks after MI; at 28 weeks after MI, animals that received 3 doses of cells exhibited a greater increase in LVEF versus those that received a single dose. 34 Our study differs from these previous investigations in many respects, including (among other) the type of cell used, the animal model (reperfused and old MI), the methods to quantitate cell survival and fate, the measurement of cell proliferation, and the cell delivery technique (echo-guided intraventricular infusion).
Recently, Mann et al 36 reported that a second injection of bone marrow mononuclear cells in previously responding patients with refractory angina produced an improvement in myocardial perfusion, anginal symptoms, and quality of life similar to that observed after the first injection performed ≈5 years earlier. This study, however, did not compare multiple injections with 1 injection, nor did it demonstrate a cumulative effect.
Our PCR-based measurements of cell engraftment did not demonstrate a statistically significant difference between the single-and multiple-dose groups, both of which exhibited, on average, extremely low cell numbers (<4000 cells/heart). A considerable variability was observed, and it is possible that with greater sample sizes, a significantly greater content of CPCs may have been demonstrable in the multiple-dose group. Nevertheless, as each CPC infusion produced a short-lived spike of CPC concentration in the myocardium, the average tissue CPC concentration over time must have been greater in the multiple-dose group versus single-dose group, which would be expected to augment therapeutic efficacy.
This study provides a new methodology for cell delivery that may have widespread application in preclinical research. All studies of CPCs performed to date have delivered cells via either the intramyocardial or the intracoronary route, both of which necessitate an open-chest procedure. [3] [4] [5] [6] [7] [8] [9] [10] [11] Performing multiple CPC injections with either of these approaches would be highly problematic not only because of a host of technical and regulatory obstacles but also because of the mortality associated with repeated thoracotomies. These problems may be one of the reasons why repeated CPC administrations have never been investigated thus far. Our results demonstrate no myocardial retention of CPCs after intravenous infusion (Table 1) .
To overcome these obstacles, we have developed a novel percutaneous delivery method that has enabled us to infuse CPCs into the LV cavity without opening the chest and without subjecting the animal to the stress of multiple surgeries. The closed-chest, echo-guided approach described herein has allowed us to successfully perform repeated injections with very low mortality: 68 of 73 rats survived after the first infusion, 66 of the 68 survived after the second infusion, and 64 of the 66 survived after the third infusion, for a total mortality of 12.3% (Online Table I ). Importantly, our PCRbased measurements of CPC retention at 24 hours after infusion demonstrated that the number of cells present in the heart was similar to that found 24 hours after intracoronary (open-chest) delivery (Table 1 ). The echo-guided percutaneous approach described herein was safe and well tolerated and can be repeated several times, potentially even >3×. Therefore, our results introduce a new method that enables, for the first time, repeated cell administrations in rodents. This method is likely to be useful to investigators interested in maximizing the benefits of cell therapy. Repeated administration of cells is clinically relevant and eminently feasible in patients: once cells have been expanded, they can be frozen and stored for subsequent injection, which could be repeated at periodic intervals until the desired therapeutic effect is achieved, particularly in patients with ischemic cardiomyopathy, in whom the chronic nature of heart failure lends itself to repeated cell treatments.
What is the mechanism of the salubrious effects of repeated CPC administrations? Consistent with our previous studies, [4] [5] [6] [7] 19 we found that, regardless of the number of treatments, very few transplanted CPCs engrafted and, of those, only a small fraction differentiated into mature cardiac myocytes, accounting for <1% of total myocytes ( Figure 9E) . Consequently, the additive effects of repeated CPC infusions must be mediated by paracrine actions, just like those of a single CPC infusion. Among these actions could be decreased fibrosis in the noninfarcted region ( Figure 6D ) and formation of new myocytes in the risk region, which is supported by the increase in BrdU POS /cTnI POS and IdU POS /cTnI POS cells (Figure 8 ), the decrease in myocyte cross-sectional area ( Figure 7B ), and the increase in myocyte density ( Figure 7C ) in the risk region of the multiple-dose group. Also consistent with our previous studies, [4] [5] [6] [7] 19 we found that CPC administration triggered a prolonged proliferative response in the risk region, the significance of which remains unclear. We have previously found that this phenomenon involves proliferation of endogenous CPCs, endothelial cells, and small cells expressing α-sarcomeric actin. [4] [5] [6] [7] 19 Alternatively, or in addition, the BrdU POS and IdU POS cells may be newly formed inflammatory cells originating in the bone marrow or spleen that infiltrate the risk region.
The present results have potentially far-reaching implications for the field of cell therapy. For example, in all clinical trials and almost all preclinical investigations conducted thus far, conclusions about whether a cell product was or was not effective have been based on the outcome of one cell administration. Our finding that the full effects of CPC administration require repeated treatments implies that the efficacy of cell therapy cannot be properly evaluated after a single dose. Just as it would not be appropriate to assess the efficacy of an antibiotic on the basis of 1 dose, so it is not appropriate to assess the efficacy of a cell product on the basis of 1 treatment. If this new paradigm is applicable to other cell types and model systems, the conclusions of previous "negative" preclinical and clinical trials (which have used one dose of cells) could be questioned, and the protocols of future preclinical and clinical trials may have to be changed.
In conclusion, enthusiasm for cell therapy has been dampened by the modest or inconsistent improvement in LV function reported in many preclinical and clinical investigations. This study identifies a possible reason for these results. We provide here the first demonstration that repeated CPC administrations are more effective than a single administration, and markedly so. In this rat model of chronic ischemic cardiomyopathy, each cell dose resulted in a similar increase in regional and global LV function, such that the cumulative improvement produced by 3 doses was roughly triple than that produced by a single dose.
This concept may have major implications for both preclinical and clinical studies of cell therapy in general because it implies that the protocols used heretofore (with a single dose of cells) may not have been adequate to test the efficacy of the treatment. In addition, we have described a new method that enables studies of repeated cell administrations in rodents.
What Is Known?
• All previous studies of c-kit POS cardiac progenitor cells (CPCs), and almost all preclinical and clinical studies of cell therapy in general, have assessed efficacy, or lack thereof, on the basis of one cell administration.
• The effects of one administration of CPCs (and of cell therapy in general) on left ventricular (LV) function have been regarded as modest or inconsistent.
• CPCs, and virtually all other types of cells tested heretofore, disappear quickly after transplantation, with minimal engraftment.
What New Information Does This Article Contribute?
• In rats with chronic ischemic cardiomyopathy (old myocardial infarction) that received 3 doses of CPCs 35 days apart, each cell dose resulted in a similar increase in regional and global LV function, such that the total cumulative improvement was roughly triple that produced by a single dose.
• Three CPC administrations were also associated with more viable tissue and less scar, less collagen in the risk and noninfarcted regions, and greater myocyte density in the risk region.
• Regardless of the number of treatments, few transplanted CPCs engrafted and, of those, only a small fraction differentiated into mature cardiac myocytes, accounting for <1% of total myocytes.
• This study provides a new method that enables, for the first time, repeated administrations of cells in rodents.
Although numerous cell types have been studied for the treatment of ischemic cardiomyopathy, enthusiasm for cell-based therapy has been dampened by the modest or inconsistent improvement in LV function reported in many preclinical and clinical investigations. This study identifies a possible reason for these results. We provide here the first demonstration that repeated CPC administrations are more effective than a single administration, and markedly so. This concept may have major implications for both preclinical and clinical studies of cell therapy. For example, in all clinical trials and almost all preclinical investigations conducted thus far, conclusions about whether a cell product was effective or not have been predicated on the outcome of 1 cell administration. However, our finding that the full effects of CPC administration require repeated treatments implies that the efficacy of cell therapy cannot be properly evaluated after a single dose. This constitutes a veritable paradigm shift. If this new paradigm is applicable to other cell types and model systems, the conclusions of previous "negative" preclinical and clinical trials (which have used 1 dose of cells) may be questioned (because a beneficial effect may have been missed), and the protocols of future preclinical and clinical trials may have to be changed to incorporate repeated treatments.
Novelty and Significance
radical production that have a cumulative effect on contractile function. A pathophysiological basis for chronic myocardial "stunning". 
SUPPLEMENTARY MATERIAL MATERIALS AND METHODS
All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (Eighth Edition, Revised 2010) and with the guidelines of the Animal Care and Use Committee of the University of Louisville, School of Medicine (Louisville, KY, USA).
Isolation, culture, and transfection of c-kit POS CPCs. CPCs were isolated from the entire heart (atria and ventricles) of adult male Fischer 344 rats as described. 1 The tissues were cut into small pieces (<1 mm 3 ) and suspended in 15 ml of Ham's F12 medium (Gibco) containing 1,600 units/ml of collagenase II (Worthington Labs). After 45 min of digestion, cells were plated into T75 flasks containing Ham's F12 medium supplemented with 10% fetal bovine serum (Seradigm), 5% horse serum (Gibco), 10 ng/ml recombinant human basic fibroblast growth factor (PeproTech), 10 ng/ml leukemia inhibitor factor (Millipore), 5 mU human erythropoietin (Sigma), 0.2 mM L-glutathione (Sigma), and 50 μg/ml porcine gelatin (Sigma). Cells were expanded for 5 days and subjected to immunomagnetic sorting for c-kit. Cells were then trypsinized, resuspended in 1 ml/10 7 cells of MACS buffer (Miltenyi), and then incubated with 50 µl/10 7 cells of anti-c-kit antibody (H-300, Santa Cruz) for 30 min on ice. After washing, cells were resuspended in 240 µl/10 7 cells of MACS buffer and incubated with 60 µl/10 7 cells of microbeads (anti-rabbit microbeads, Miltenyi) for 15 min at 4°C. After washing, cells were applied onto an LS column (Miltenyi) and the positive fraction was plated into a T25 flask. The c-kit POS CPCs were transfected at passage 2 or 3 with a lentiviral vector expressing GFP or mCherry protein. After selection with blasticidin (Invitrogen) and fluorescence-activated cell sorting (FACS), the GFP or mCherry positive cells were expanded and cryopreserved at passage 5 to 6. Then, cells were thawed, cultured, and injected into the rat heart at passages 6 to 8. The rationale for using male donor CPCs was that the fate of transplanted CPCs can be tracked down by detecting Y-chromosome pos cells, although previous studies have suggested that bone marrow-derived mesenchymal stromal cells differ significantly between male and female sources, with female cells usually performing more robustly. 2 Characterization of c-kit POS CPCs. Small samples of CPCs were fixed in 4% paraformaldehyde for 20 min at room temperature at the same passage that was used for injection. Fixed cells were incubated for 1 h at room temperature with an antibody against c-kit (C19), a hematopoietic lineage marker (CD45), an endothelial marker (CD31), or mesenchymal markers (CD90/105/73/29). Then, cells were incubated for 1 h at room temperature with a secondary antibody if the primary antibodies were not directly conjugated. FACS analysis was done with Accuri C6 (Accuri Cytometers) or BD LSR II (BD Biosciences) instruments. 1 Surgical procedures. The rat model of old MI has been described previously. 3 Briefly, adult female Fischer 344 rats (age, 4 months; weight 175 ± 2 g) were anesthetized with ketamine (37 mg/kg) and xylazine (5 mg/kg), intubated, and ventilated with a rodent respirator. Anesthesia was maintained with 1% isoflurane inhalation and body temperature was kept at 37°C with a heating pad. After administration of antibiotics, the chest was opened and the heart was exposed. All rats underwent a 2-h occlusion of the left anterior descending coronary artery followed by reperfusion. Ketoprofen was given for three days after surgery (5 mg/kg).
Treatment protocol. Thirty days after surgery, the animals were randomly allocated to three treatment groups: vehicle (control), single dose, or multiple doses (Fig. 1) . Randomization was performed using the MS Excel random group generator. All rats received an echo-guided intraventricular injection, which was performed using the Vevo 2100 Imaging System (VisualSonics) equipped with a 20-MHz transducer, a Vevo Image Station with Injection Mount and micro-manipulation controls, and a Chemyx NanoJet Stereotaxic syringe pump (Chemyx Inc. TX). Before the procedure, rats were anesthetized with 3% isoflurane. The anterior chest was shaved and the animals were placed on the imaging table in the right lateral decubitus position with the left lateral side facing the injection mount. Light anesthesia was maintained with 1% isoflurane. With the imaging transducer aligned perpendicularly to the injection mount, the left ventricle was initially imaged in the parasternal plane and a good 2D long-axis view was procured by adjusting the angle and position of the imaging table. The transducer was then turned 90 degrees clockwise and the left ventricle was scanned in the 2D short-axis and color Doppler views from apex to base to determine the optimal site for needle insertion, a site that did not include the infarct scar or a coronary artery. Under the guidance of a real-time B-mode view, a 30 G injection needle (1" length) was then carefully inserted from the left lateral side using the micro-manipulation controls and advanced into the center of the LV cavity.
Rats received an infusion of CPCs (12 x 10 6 cells in 5 ml of DPBS (Dulbecco's phosphatebuffered saline, Gibco) or vehicle (5 ml of DPBS) into the LV cavity with the injection pump at a rate of 1.25 ml/min for 4 min. The single-dose and multiple-dose groups received CPCs whereas the vehicle group received DPBS. Thirty-five days later, this procedure was repeated; rats received a second infusion of CPCs (multiple-dose group) or an infusion of DPBS (singledose and vehicle groups). Thirty-five days later, rats received a third infusion of CPCs (multiple-dose group) or another infusion of DPBS (single-dose and vehicle groups). mCherrylabeled CPCs were used for the 1 st treatment, non-labeled CPCs for the 2 nd treatment, and GFPlabeled CPCs for the 3 rd treatment. To monitor formation of new cells, in all groups 5-bromo-2'-deoxyuridine (BrdU, Sigma) was given for 35 days after the 1 st treatment and 5-iodo-2'-deoxyuridine (IdU, Sigma) for 35 days after the 3 rd treatment (both were given in the drinking water at a final concentration of 0.1%). At 35 days after the 3 rd treatment, rats were subjected to hemodynamic studies and euthanized for histologic studies or PCR analysis (Fig. 1) .
Before initiating the protocol, pilot studies were conducted to identify a dose of CPCs that would results in LV myocardial retention similar to that observed after intracoronary infusion of 1 million CPCs, the dose used in our previous studies in rats. 1, 3, 4 Rats underwent a 90-min coronary occlusion and reperfusion. Four hours after reperfusion, they received 1.0   CPCs (in 1 ml of DPBS) via intracoronary infusion as in our previous studies 1, 3-5 , 3.0, 9.0, or 12.0   CPCs (in 5 ml of DPBS over 4 min) using echo-guided injection into the LV cavity, or 3.0x10 6 CPCs i.v.. Rats were euthanized 24 h after CPC delivery and the heart was harvested to measure the number of CPCs in the tissue by real-time PCR.
Echocardiographic studies. All echocardiographic analyses were performed by investigators who were blinded to treatment allocation. Serial echocardiograms were obtained at five time-points: baseline (three days before coronary artery occlusion), 30 days after MI (before the 1 st treatment), 35 days after the 1 st treatment (before the 2 nd treatment), 35 days after the 2 nd treatment (before the 3 rd treatment), and 35 days after the 3 rd treatment (before euthanasia) (Fig.  1 of the main manuscript) . The echocardiographic studies were performed as described 1, 3-5 using a Vevo 2100 Imaging System equipped with a 20-MHz transducer. Briefly, rats were lightly anesthetized with 3% isoflurane. The anterior chest was shaved and the animals were placed in the left lateral decubitus position. A rectal temperature probe was inserted, and the body temperature was carefully maintained between 37.0-37.5°C with a heating pad throughout the study. Anesthesia was maintained with 1% isoflurane. The parasternal longaxis and parasternal short-axis views were used to obtain 2D and M-mode images for the measurement of LV mass, end-diastolic and end-systolic thickness of the infarcted wall (IWTd and IWTs, respectively) and posterior (noninfarcted) wall (PWTd and PWTs), infarcted and posterior LV wall systolic thickening fraction (ThF) (IWThF and PWThF), end-diastolic and end-systolic LV volume (LVEDV and LVESV), stroke volume (SV), cardiac output (CO), ejection fraction (EF), and fractional area change (FAC). 1, [3] [4] [5] The akinetic endocardial length (AL), expressed as a percentage of the entire LV endocardial length, was also calculated. 6 Measurements were performed according to the American Society for Echocardiography, and were averaged over three consecutive cardiac cycles.
Hemodynamic studies. All hemodynamic analyses were performed by investigators who were blinded to treatment allocation. The hemodynamic studies were conducted 35 days after the 3 rd treatment, just before euthanasia (Fig. 1) . The protocol has been described. 1, 3, 5 Briefly, rats were anesthetized with 2-3% isoflurane, intubated, and mechanically ventilated. Anesthesia was maintained with 1% isoflurane and the core temperature carefully kept at 37.0°C with a heating pad throughout the study. A 2F microtip pressure-volume (PV) catheter (SPR-869, Millar Instruments) was inserted into the right carotid artery and advanced into the LV cavity. The right jugular vein was cannulated for fluid administration. After 30 min of stabilization, the PV signals were recorded continuously with an ARIA PV conductance system (Miller Instruments) coupled with a Powerlab/4SP A/D converter (AD Instruments), stored, and displayed on a personal computer. PV relations were assessed by transiently compressing the inferior vena cava with a cotton swab. Parallel conductance from surrounding structures was calculated by injecting a small bolus of 15% NaCl through the jugular vein. Hemodynamic indexes were calculated using the PVAN3.2software (Millar Instruments). 1, 3, 5 Histologic studies. The protocol for histologic analyses has been described. 1, 3, 5 Briefly, after the hemodynamic measurements, a polyethylene catheter filled with phosphate buffer (0.2 M, pH 7.4) and heparin (100 IU/ml) was advanced to the ascending aorta via the right carotid artery. In rapid succession, the heart was arrested in diastole by injecting 1 ml of a mixture of cadmium chloride (100 mM)/potassium chloride (3 M) through the aortic catheter. The heart was then excised and perfused retrogradely with phosphate buffer for ~3 min to flush out residual blood in the coronary circulation, followed by perfusion with 10% neutral buffered formalin solution for 10 min. Perfusion pressure was maintained between 60 and 80 mmHg while end-diastolic pressure was kept at 8 mmHg. After perfusion-fixation, the atria and right ventricle were dissected from the left ventricle. The LV weight was measured; LV volume was calculated as the difference between the weight of the water-filled and empty left ventricle by converting weight to volume (1 g H 2 O = 1 ml H 2 O). 1, 3, 5, 7 The heart was cut into four transverse slices (~2 mm thick), which were processed, embedded in paraffin, sectioned at 4-μm intervals, and stained with Masson's trichrome, picrosirius red, or antibodies against GFP, mCherry and cell-type specific markers. Images were acquired digitally and analyzed using NIH ImageJ (1.48v). From the Masson's trichromestained images, morphometric parameters including total LV area, risk region area, scar area, and LV wall thickness in the risk and noninfarcted regions were measured in each section. 1, 3, 5 Myocardial collagen content was quantitated on picrosirius red-stained heart images acquired under polarized light microscopy by determining collagen density (arbitrary unit) per mm 2 of risk region or noninfarcted region with NIH ImageJ software. 1, 3 Immunohistochemistry. Immunohistochemistry was performed in formalin-fixed, paraffinembedded, 4-µm-thick heart sections. CPC proliferation was assessed by immunofluorescent staining of nuclei with specific antibodies for BrdU and IdU (Santa Cruz). Myocytes were stained with anti-cardiac troponin I (cTnI) antibody (Santa Cruz) or with anti-α-sarcomeric actin (α-SA) antibody (Sigma). Myocyte membranes were stained with FITC-conjugated wheat germ agglutinin (WGA) (Sigma) to facilitate the identification of individual myocytes for analysis of myocyte cross-sectional area and myocyte density. To determine vessel density, heart sections were stained with specific FITC-conjugated Isolectin B4 (IB4) antibody (Sigma). 8 Triplicate immunofluorescent staining was conducted with specific anti-BrdU, anti-IdU, and anti-cTnI antibodies for evaluation of proliferating myocytes, and with specific anti-BrdU, antiIdU, and anti-Isolectin B4 antibodies for evaluation of proliferating vessels. Nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole).
Fluorescent in situ hybridization (FISH) analysis. To assess the fate of the transplanted male CPCs, single-labeled Y chromosome was detected by fluorescence in situ hybridization (FISH) according to the modified manufacturer's protocol (ID Labs, London, ON). 1, 9 4-μm-Thick serial tissue sections were cut from paraffin-embedded heart blocks. Heart tissue sections on coated slides were deparaffinized in xylene and rehydrated gradually, followed by an antigen retrieval procedure. After treatment with pepsin and air-drying, a denatured rat FITCconjugated Y chromosome probe was added to each section and covered by coverslip. After overnight hybridization at RT°C, the coverslip was removed and serial washings were performed. Male and female rat heart tissue sections were used as positive and negative controls, respectively, in the FISH staining procedure. Proliferation of transplanted male CPCs in the heart was assessed by triplicate fluorescent staining with a FITC-conjugated Ychromosome probe and specific anti-BrdU and anti-IdU antibodies (Santa Cruz). Myocardial morphology was examined with the confocal transmitted light channel's detector (ChD) in which the pseudocolor selected for myocardial background in the ChD channel was gray white. Nuclei were counterstained with DAPI. To minimize auto fluorescence, slides were incubated with 0.1% Sudan Black B (Sigma), rinsed in PBS, and then mounted with ProLong Gold antifade reagent (Invitrogen). 10 Immunohistochemical signals were imaged by confocal microscopy and quantitatively analyzed by Image J (1.46, NIH). In each heart, Ychromosome POS nuclei, Y-chromosome POS myocytes, Y-chromosome POS /BrdU POS myocytes, Ychromosome POS /IdU POS myocytes, Y-chromosome POS /BrdU POS /IdU POS myocytes , total myocytes, and total nuclei were counted in 25 confocal images (5 from each border zone, 10 from the scar region, and 5 from the noninfarcted region). For Y-chromosome POS nuclear analysis, an average of 1,274 nuclei was counted in a 0.354 mm 2 area per rat heart (n=8/group).
Measurement of transplanted cells by real-time PCR.
To determine the absolute number of transplanted CPCs, a quantitative real-time PCR-based method was used as previously described. 11, 12 A subset of hearts from the single-dose group (n=8) and the multiple-dose group (n=11) were frozen just after excision. The left ventricle was divided into two regions: the risk region (anterior wall and septum), which included the border zone, and the noninfarcted region (posterior LV wall). The tissue samples were placed in screw-cap tubes containing an excess volume of Buffer ATL (tissue lysis buffer) plus Proteinase K. The internal standard (250,000 female human peripheral mononuclear cells [hPBMCs]) was resuspended using 50 μl of the above tissue digestion solution and added to each tube. After overnight incubation, the samples were treated with RNase A (Qiagen) to prevent RNA contamination of genomic DNA. The DNA concentrations of the samples were measured using standard UV spectrophotometry. For each real-time PCR, 200 ng of genomic DNA was amplified in a 20-μl reaction using SYBR Green PCR Master Mix and a StepOne Plus real-time PCR machine. Each sample was run in triplicate and analyzed using the following sets of primers: rat Sry (for male rat DNA) 5'-TGCAGCGTGAAGTTGCCTCAACA-3' and 5'-ACTGGTGTGCAGCTCTAGCCCA-3'; HLA-DMA (for human DNA) 5'-TACAAACCTCAGCTACCTTCGTGGC-3' and 5'-AACCCAGCTGACTCTGGGTGG-3'; rat Gapdh (for total rat DNA) 5'-GCGCATGCCGGTCTGGCTAA-3' and 5'-CGAGCCTTCCCCAGGTCCGA-3'. The amount of target DNA (human and male rat DNA) present in the PCR sample was calculated using the corresponding standard curve. The total number of cells present in each tissue was calculated using the following equation: F = (f*H)/h, where F, total number of (female) rat cells in the tissue; f, number of rat cells represented in the DNA sample; H, total number of human cells added to the tissue sample (i.e., 250,000); h, number of human cells represented in the DNA sample. The total number of male rat CPCs present in each tissue sample was calculated using the following equation: M = (m*F)/f, where M, total number of male rat cells in the tissue and m, number of rat cells presented in the DNA sample. The above two equations can be merged into a simplified equation: M = (m*H)/h. Statistical analysis. All data are expressed as means ± SEM. Echocardiographic data were analyzed with two-way repeated-measures ANOVA followed by Student's t-tests with Bonferroni correction for intra-and inter-group comparisons, as appropriate. All parametric data including morphometric, histologic, immunohistochemical, and hemodynamic data were analyzed by one-way ANOVA followed by Student's t-tests with Bonferroni correction for inter-group comparisons. [13] [14] [15] Mortality was analyzed by the chi-square test. All analyses were conducted with SigmaStat 3.5. P values <0.05 were considered significant. 
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